SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ — Anadys
Pharmaceuticals, Inc. (Nasdaq:
ANDS) today announced the ANA598 data to be presented at the
61st Annual Meeting of the American Association for the Study of
Liver Disease (AASLD) in Boston, MA. ANA598, the Company’s
direct-acting antiviral (DAA) being developed for the treatment of
hepatitis C, will be discussed in two presentations at the
conference:
- On Sunday, October 31, 2010 at 3:00 pm Eastern Daylight Time,
Eric Lawitz, M.D., a principal investigator of the study, will give
an oral presentation titled, “Safety and Antiviral Activity of
ANA598 in Combination with Pegylated Interferon alpha 2A Plus
Ribavirin in Treatment-Naive Genotype-1 Chronic HCV Patients.”
The slides will be available on the Company’s website at www.anadyspharma.com
following conclusion of the presentation. - On Tuesday, November 2, 2010 at 7:00 am Eastern Daylight Time,
Anadys will present data in a poster titled, “IL28B Polymorphism
and Kinetics of Antiviral Activity for ANA598 in Combination with
Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naive
Genotype-1 Chronic HCV Patients.” The poster will be
available on the Company’s website at www.anadyspharma.com.
“We are pleased with the positive clinical profile seen to date
for ANA598, as well as its preclinical properties that support
investigation of combinations with other direct antivirals,” said
James L. Freddo, M.D., Senior Vice President, Drug Development and
Chief Medical Officer of Anadys. “In the upcoming Phase IIb
study, we look forward to testing ANA598 for the first time in
treatment-experienced patients, as well as in a larger population
of treatment-naive patients.”
In the oral pr
‘/>”/>
